Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: A comparative study

Human Pathology

Volumn 45, Issue 7, 2014, Pages 1529-1540

  Ordóñez, Nelson G ^a   Sahin, Aysegul A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast carcinoma; Calretinin; GATA3; Immunohistochemistry; Mesothelin; Mesothelioma; Triple negative breast carcinoma

Indexed keywords

CALRETININ; CLAUDIN 4; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN; MESOTHELIN; PODOPLANIN; PROTEIN; THROMBOMODULIN; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UNCLASSIFIED DRUG; WT1 PROTEIN;

ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; EPITHELIOID PLEURAL MESOTHELIOMA; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MESOTHELIOMA; TRIPLE NEGATIVE BREAST CANCER;

BREAST CARCINOMA; CALRETININ; GATA3; IMMUNOHISTOCHEMISTRY; MESOTHELIN; MESOTHELIOMA; TRIPLE-NEGATIVE BREAST CARCINOMA;

ADENOCARCINOMA; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 84903179564     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.03.006     Document Type: Article

References (93)

1. B. Chernow, and S.A. Sahn Carcinomatous involvement of the pleura: an analysis of 96 patients Am J Med 63 1977 695 702 (Pubitemid 8222934)
2. R.L. Attanoos, and A.R. Gibbs "Pseudomesotheliomatous" carcinomas of the pleura: a 10-year analysis of cases from the Environmental Lung Disease Research Group, Cardiff Histopathology 43 2003 444 452 (Pubitemid 37445235)
3. B.T.-Y. Lin, T. Colby, and A.M. Gown et al. Malignant vascular tumors of the serous membranes mimicking mesothelioma. A report of 14 cases Am J Surg Pathol 20 1996 1431 1439 (Pubitemid 26411710)
4. N.G. Ordóñez, and C. Tornos Malignant peripheral nerve sheath tumor of the pleura with epithelial and rhabdomyoblastic differentiation: report of a case clinically simulating mesothelioma Am J Surg Pathol 21 1997 1515 1521 (Pubitemid 27528264)
5. C.A. Hartmann, and C. Minck Metastatic cystosarcoma phyllodes with pseudomesotheliomatous sarcomatosis of the contralateral pleura Pathologe 9 1988 119 123 German (Pubitemid 18079915)
6. R.L. Attanoos, F. Galateau-Salle, A.R. Gibbs, S. Muller, F. Ghandour, and S.D. Dojcinov Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma Histopathology 41 2002 42 49 (Pubitemid 34779680)
7. R.L. Attanoos, and A.R. Gibbs Pleural "pseudomesotheliomas" - a 10 year analysis (1990-2000) Eur Resp J 18 2001 534S
8. H.J. Andersen, L.G. Hansen, and S.M. Paulsen Metastasis of cancer to cancer. A case of breast carcinoma metastasizing to a malignant mesothelioma Thorac Cardiovasc Surg 34 1986 258 259 (Pubitemid 16045393)
9. H.H. Erdem, E. Kirmizigul, and C. Arslan et al. Maxillary sinus carcinoma metastases mimicking malignant pleural mesothelioma Am Surg 76 2010 E80 E82
10. G.D. Leopold, and R.L. Attanoos The importance of retaining post mortem tissue - "pseudomesotheliomatous" Merkel cell carcinoma of the pleura Histopathology 58 2011 1180 1182
11. R.L. Attanoos, D.H. Thomas, and A.R. Gibbs Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals Histopathology 43 2003 387 392 (Pubitemid 37249153)
12. N.G. Ordóñez The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma Am J Surg Pathol 27 2003 1031 1051 (Pubitemid 36909525)
13. N.G. Ordóñez The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study Mod Pathol 19 2006 417 428 (Pubitemid 43276996)
14. N.G. Ordóñez Value of PAX8, PAX2, napsin A, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma Mod Pathol 26 2013 1132 1143
15. N.G. Ordóñez Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas Mod Pathol 26 2013 553 562
16. E.E. Duhig, L. Kalpakos, I.A. Yang, and B.E. Clarke Mesothelial markers in high-grade breast carcinoma Histopathology 59 2011 957 964
17. G. Powell, H. Roche, and W.R. Roche Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma Histopathology 59 2011 950 956
18. N.G. Ordóñez Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update Hum Pathol 44 2013 1 19
19. M. Hinterberger, T. Reineke, M. Storz, W. Weder, P. Vogt, and H. Moch D2-40 and calretinin - a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation Mod Pathol 20 2007 248 255 (Pubitemid 46422180)
20. A.N. Husain, T. Colby, N. Ordóñez International Mesothelioma Interest Group Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group Arch Pathol Lab Med 137 2013 647 667
21. M. Mahalingam, L.P. Nguyen, J.E. Richards, A. Muzikansky, and M.P. Hoang The diagnostic utility of immunohistochemistry in distinguishing primary skin adnexal carcinomas from metastatic adenocarcinoma to skin: an immunohistochemical reappraisal using cytokeratin 15, nestin, p63, D2-40, and calretinin Mod Pathol 23 2010 713 719
22. N.G. Ordóñez Value of calretinin immunostaining in diagnostic pathology: a review and update Appl Immunohistochem Mol Morphol 2013 Oct 31. [Epub ahead of print]
23. K. Chang, I. Pastan, and M.C. Willingham Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium Int J Cancer 50 1992 373 381
24. N.G. Ordóñez Value of mesothelin immunostaining in the diagnosis of mesothelioma Mod Pathol 16 2003 192 197 (Pubitemid 36337423)
25. H.F. Frierson Jr., C.A. Moskaluk, and S.M. Powell et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas Hum Pathol 34 2003 605 609 (Pubitemid 36750373)
26. N.G. Ordóñez Application of mesothelin immunostaining in tumor diagnosis Am J Surg Pathol 27 2003 1418 1428 (Pubitemid 37315193)
27. N.G. Ordóñez The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study Hum Pathol 35 2004 697 710 (Pubitemid 38881080)
28. J. Tchou, L.C. Wang, and B. Selven et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer Breast Cancer Res Treat 133 2012 799 804
29. N.G. Ordóñez Value of podoplanin as an immunohistochemical marker in tumor diagnosis: a review and update Appl Immunohistochem Mol Morphol 2013 Mar 25. [Epub ahead of print]
30. A.Y. Chu, L.A. Litzky, T.L. Pasha, G. Acs, and P.J. Zhang Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma Mod Pathol 18 2005 105 110 (Pubitemid 40128102)
31. N.G. Ordóñez D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma Hum Pathol 36 2005 372 380 (Pubitemid 40591807)
32. A.V. Bassarova, J.M. Nesland, and B. Davidson D2-40 is not a specific marker for cells of mesothelial origin in serous effusions Am J Surg Pathol 30 2006 878 882 (Pubitemid 44264979)
33. A. Fernandez-Flores Podoplanin immunostaining in cutaneous apocrine carcinoma and in cutaneous metastasis from the breast Appl Immunohistochem Mol Morphol 18 2010 573 574
34. J.R. Riera, C. Astengo-Osuna, J.A. Longmate, and H. Battifora The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval Am J Surg Pathol 21 1997 1409 1419 (Pubitemid 27528251)
35. N.G. Ordóñez Thrombomodulin expression in transitional cell carcinoma Am J Clin Pathol 110 1998 385 390 (Pubitemid 28406998)
36. P.M. Cury, D.N. Butcher, C. Fisher, B. Corrin, and A.G. Nicholson Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura Mod Pathol 13 2000 107 112 (Pubitemid 30109095)
37. N.G. Ordóñez Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma Am J Surg Pathol 24 2000 598 606 (Pubitemid 30180755)
38. K. Kushitani, Y. Takeshima, V.J. Amatya, O. Furonaka, A. Sakatani, and K. Inai Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma Pathol Int 57 2007 190 199 (Pubitemid 46279947)
39. H. Hwang, L. Quenneville, H. Yaziji, and A.M. Gown Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin Appl Immunohistochem Mol Morphol 12 2004 122 126 (Pubitemid 38788760)
40. W. Zhu, and C.W. Michael WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions Diagn Cytopathol 35 2007 370 375 (Pubitemid 46835030)
41. D. Nonaka, L. Chiriboga, and R.A. Soslow Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas Am J Surg Pathol 32 2008 1566 1571
42. J.E. Armes, G. Bowlay, R. Lourie, D.J. Venter, and G. Price Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: an immunohistochemical approach Pathology 42 2010 534 539
43. F. Facchetti, S. Lonardi, and F. Gentili et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions Virchows Arch 451 2007 669 680 (Pubitemid 47340982)
44. N.G. Ordóñez Value of claudin-4 immunostaining in the diagnosis of mesothelioma Am J Clin Pathol 139 2013 611 619
45. Y. Soini, V. Kinnula, K. Kahlos, and P. Pääkkö Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura J Clin Pathol 59 2006 250 254 (Pubitemid 43344884)
46. C. Edwards, and J. Oates OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed and paraffin wax embedded material J Clin Pathol 48 1995 626 630
47. N.G. Ordóñez Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma Hum Pathol 29 1998 166 169 (Pubitemid 28099512)
48. R.J. Barnetson, R.A. Burnett, I. Downie, C.M. Harper, and F. Roberts Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful Am J Clin Pathol 125 2006 67 76 (Pubitemid 43089727)
49. N.G. Ordóñez Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature Am J Clin Pathol 109 1998 85 89 (Pubitemid 28023815)
50. N.G. Ordóñez The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies Am J Surg Pathol 21 1997 1399 1408 (Pubitemid 27528250)
51. C.E. Comin, L. Novelli, V. Boddi, M. Paglierani, and S. Dini Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma Hum Pathol 32 2001 529 536 (Pubitemid 32506524)
52. N.G. Ordóñez The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study Mod Pathol 19 2006 34 48 (Pubitemid 43250977)
53. W.T. McCaughey, T.V. Colby, and H. Battifora et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel Mod Pathol 4 1991 342 353
54. M. Miettinen, J. Limon, A. Niezabitowski, and J. Lasota Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma Am J Surg Pathol 25 2001 610 617 (Pubitemid 32423358)
55. M.R. Wick, T.J. Lillemoe, G.T. Copland, P.E. Swanson, J.C. Manivel, and D.T. Kiang Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin Hum Pathol 20 1989 281 287 (Pubitemid 19081966)
56. P.E. Swanson, G. Pettinato, T.J. Lillemoe, and M.R. Wick Gross cystic disease fluid protein-15 in salivary gland tumors Arch Pathol Lab Med 115 1991 158 163
57. S. Ansai, S. Koseki, Y. Hozumi, and S. Kondo An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation Am J Dermatopathol 17 1995 249 255
58. A. Perry, J.E. Parisi, and P.J. Kurtin Metastatic adenocarcinoma to the brain: an immunohistochemical approach Hum Pathol 28 1997 938 943 (Pubitemid 27355554)
59. J.M. Striebel, S. Dacic, and S.A. Yousem Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma Am J Surg Pathol 32 2008 426 432 (Pubitemid 351398935)
60. M. Yang, and D. Nonaka A study of immunohistochemical differential expression in pulmonary and mammary carcinomas Mod Pathol 23 2010 654 661
61. C. Tornos, R. Soslow, and S. Chen et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary Am J Surg Pathol 29 2005 1482 1489 (Pubitemid 41513298)
62. R. Bhargava, S. Beriwal, and D.J. Dabbs Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity Am J Clin Pathol 127 2007 103 113 (Pubitemid 46797025)
63. F.R. Fritzsche, A. Thomas, and K.J. Winzer et al. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer Histol Histopathol 22 2007 1221 1230 (Pubitemid 47470316)
64. M.H. Luo, Y.H. Huang, and Y.B. Ni et al. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas Hum Pathol 44 2013 1241 1250
65. G.H. Lewis, A.P. Subhawong, and H. Nassar et al. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin Am J Clin Pathol 135 2011 587 591
66. E.E. Pala, Ü. Bayol, S. Cumurcu, and E. KeskIn Immunohistochemical characteristics of triple negative/basal-like breast cancer Turk Patoloji Derg 28 2012 238 244
67. L. Huo, J. Zhang, and M.Z. Gilcrease et al. Gross cystic disease fluid protein-15 and mammaglobin A expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer Histopathology 62 2013 267 274
68. Y. Takeda, K. Tsuta, and Y. Shibuki et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors Arch Pathol Lab Med 132 2008 239 243 (Pubitemid 351213793)
69. L. Miele, E. Cordella-Miele, G. Mantile, A. Peri, and A.B. Mukherjee Uteroglobin and uteroglobin-like proteins: the uteroglobin family of proteins J Endocrinol Invest 17 1994 679 692
70. J.-H. Han, Y. Kang, and H.-C. Shin et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma Arch Pathol Lab Med 127 2003 1330 1334 (Pubitemid 37248330)
71. E. Sasaki, N. Tsunoda, Y. Hatanaka, N. Mori, H. Iwata, and Y. Yatabe Breast-specific expression of MGB1/mammaglobin: an examination of 480 tumors from various organs and clinicopathological analysis of MGB1-positive breast cancers Mod Pathol 20 2007 208 214 (Pubitemid 46422175)
72. A. Ciampa, G. Fanger, A. Khan, K.L. Rock, and B. Xu Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas Cancer 102 2004 368 372 (Pubitemid 39620246)
73. Z. Yan, J. Gidley, D. Horton, J. Roberson, I.E. Eltoum, and D.C. Chhieng Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens Diagn Cytopathol 37 2009 475 478
74. M.L. Asselin-Labat, K.D. Sutherland, and H. Barker et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation Nat Cell Biol 9 2007 201 209 (Pubitemid 46420863)
75. N.G. Ordóñez Value of GATA3 immunostaining in tumor diagnosis: a review Adv Anat Pathol 20 2013 352 360
76. N.G. Ordóñez Value of GATA3 immunostaining in the diagnosis of parathyroid tumors Appl Immunohistochem Mol Morphol 20 2013 352 360
77. M. Miettinen, P.A. McCue, and M. Sarlomo-Rikala et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors Am J Surg Pathol 38 2014 13 22
78. P. Parikh, J.P. Palazzo, L.J. Rose, C. Daskalakis, and R.J. Weigel GATA-3 expression as a predictor of hormone response in breast cancer J Am Coll Surg 200 2005 705 710 (Pubitemid 40569542)
79. A. Cakir, O. Ekinci, I. Isik Gonul, B. Cetin, M. Benekli, and O. Uluoglu GATA3 expression and relationship between clinicopathological parameters in invasive breast carcinomas (abstract) Mod Pathol 26 Suppl 2 2013 32A
80. G. Deftereos, U. Krishnamurti, and J.F. Silverman GATA3 expression in different subtypes of invasive breast carcinoma and comparison with GCDFP15 and mammaglobin (abstract) Mod Pathol 26 Suppl 2 2013 36A
81. N. Gonzalez-Roibon, A. Chaux, R. Sharma, M.E. Allaf, and G.J. Netto The role of GATA3 in the differential diagnosis of upper tract urothelial and collecting duct carcinomas (abstract) Mod Pathol 26 Suppl 2 2013 213A
82. M. Surowiecka, C. Blair, D. Knapp, L. Varghese, and E. Gulbahce Significance of GATA3 expression in outcomes of breast cancer patients who received systemic chemo and/or hormonal therapy and clinicopathological features of GATA3 positive tumors (abstract) Mod Pathol 26 Suppl 2 2013 71A
83. A. Cimino-Mathews, A.P. Subhawong, and P.B. Illei et al. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas Hum Pathol 44 2013 1341 1349
84. A. Albergaria, J. Paredes, and B. Sousa et al. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours Breast Cancer Res 11 2009 R40
85. R.S. Gonzalez, J. Wang, T. Kraus, H. Sullivan, A.L. Adams, and C. Cohen GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance Hum Pathol 44 2013 1065 1070
86. R.V. Hoch, D.A. Thompson, R.J. Baker, and R.J. Weigel GATA-3 is expressed in association with estrogen receptor in breast cancer Int J Cancer 84 1999 122 128 (Pubitemid 29133821)
87. V. Ciocca, C. Daskalakis, R.M. Ciocca, A. Ruiz-Orrico, and J.P. Palazzo The significance of GATA3 expression in breast cancer: a 10-year follow-up study Hum Pathol 40 2009 489 495
88. N.K. Yoon, E.L. Maresh, and D. Shen et al. Higher levels of GATA3 predict better survival in women with breast cancer Hum Pathol 41 2010 1794 1801
89. N.G. Ordóñez Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas Hum Pathol 36 2005 1163 1167 (Pubitemid 41541966)
90. N.G. Ordóñez Napsin A, expression in lung and kidney neoplasia: a review and update Adv Anat Pathol 19 2012 66 73
91. N.G. Ordóñez Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update Appl Immunohistochem Mol Morphol 20 2012 429 444
92. N.G. Ordóñez Value of PAX 8 immunostaining in tumor diagnosis: a review and update Adv Anat Pathol 19 2012 140 151
93. N.G. Ordóñez Value of PAX2 immunostaining in tumor diagnosis: a review and update Adv Anat Pathol 19 2012 401 409